GlassScriptPhysician profile
Anna Nicole Rawdon
NPI 1225270705
$708.63
in general payments reported to CMS, 2019-2025
17 companies · $81.98 in 2025
The $81.98 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $17.73 · 2022: $11.85 · 2023: $182 · 2024: $415 · 2025: $81.98.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $629 · Education: $50.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $629.05 |
| Education | $50.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corcept Therapeutics | $229.98 | 2024-2025 | Korlym |
| Novo Nordisk INC | $82.78 | 2023-2024 | Wegovy, Ozempic, Rybelsus |
| Currax Pharmaceuticals LLC | $50.00 | 2023 | Nexletol |
| Pfizer INC. | $49.40 | 2023-2024 | |
| Amneal Pharmaceuticals LLC | $39.89 | 2024 | Unithroid |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $31.76 | 2023 | Trulance, Xifaxan |
| Ibsa Pharma INC. | $31.29 | 2023-2024 | Tirosint, Licart, Tirosint |
| Astrazeneca Pharmaceuticals LP | $30.16 | 2024-2025 | Saphnelo |
| Antares Pharma, INC. | $23.38 | 2024 | Xyosted |
| Astellas Pharma US INC | $22.68 | 2024 | Veozah |
| Sandoz INC. | $21.76 | 2025 | Hyrimoz |
| Abbvie INC. | $20.95 | 2023 | |
| Allergan, INC. | $17.73 | 2021 | |
| Fresenius Kabi USA, LLC | $15.69 | 2025 | |
| Axsome Therapeutics, INC. | $15.05 | 2025 | Sunosi |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Azurity Pharmaceuticals, INC. | $14.28 | 2023 | Adthyza |
| Lilly USA, LLC | $11.85 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anna Rawdon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.